GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

ImmuPharma IMM.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

3.24p

-1.52%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

ImmuPharma — daily IMM

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View ImmuPharma on TradingView ↗
Market value
£13.5m
Last close × shares
Volume
3.7m
Shares, 9 Nov 2026

About ImmuPharma

Its shares trade on LSE under the ticker IMM.L. It has been listed since 28 October 2003. In the fiscal year to 31 December 2021, it reported revenue of £118,350 and a net loss of £8.2m. At that date it held total assets of £6.0m and shareholders' equity of £4.4m.

ImmuPharma Plc engages in the research, development, and commercialization of pharmaceutical products. The firm is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The firm has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The firm's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The firm's research operations are in France.

Figures and description from our data supplier, not checked against the company's own report.

More about ImmuPharma →

Latest on ImmuPharma

Our reporting

We have not reported on ImmuPharma yet.

Next results

25 May 2027

Due on 25 May 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is ImmuPharma's ticker?

ImmuPharma trades as IMM.L on LSE, under ISIN GB0033711010.

What was ImmuPharma's last closing price?

3.24p on 9 Nov 2026. The figure is in GBp and is never converted.

When does ImmuPharma next report results?

Results are expected on 25 May 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.